Israel’s BiolineRX is to conduct Phase 1 clinical trials on sickle cell disease (SCD) patients at multiple locations in the US.  It will use its motixafortide stem cell therapy (see here previously), currently used to treat multiple myeloma. SCD is … Continue reading →

This article identifies three more Israeli companies that are expected to receive FDA approval for treatments in 2023. They are Gamida Cell (Omidubicel / NiCord – bone marrow transplants); Protalix (PRX-102 – Fabry disease); and BioLineRX (BL-8040 / Motixafortide – … Continue reading →

Israel’s BioLineRx (see here previously) has reported positive results in the Phase 3 trial of its Motixafortide treatment in combination with G-CSF for multiple myeloma. The treatment demonstrated improvement from five-fold to 14-fold compared to the control. https://en.globes.co.il/en/article-biolinerx-soars-on-positive-phase-3-blood-cancer-trial-results-1001347840 https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-positive-top-line-results-genesis-phase-3

The European Commission has just granted Orphan drug status to the BL-8040 (Motixafortide) pancreatic cancer treatment from Israel’s BioLineRX (see here). BioLineRX can now receive benefits including EU funding, less regulation, and market exclusivity. https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-receives-orphan-drug-designation-motixafortide-bl-8040